N-Methyl-N′-nitro-N-nitrosoguanidine treatment of human peripheral blood mononuclear cells increases the frequency of lymphocyte transformation into permanently proliferating lines. The transformation is dependent on the dose of N-methyl-N′-nitro-N-nitrosoguanidine and does not occur in the presence of autologous human serum. Thirty-eight of the forty-two established lines resulting from N-methyl-N′-nitro-N-nitrosoguanidine treatment produced detectable Epstein-Barr virus antigens.


Supported in part by grants from the NIH (GM07816, Cancer Center CA 14599-01), the Atomic Energy Commission [AT (11-1) 2040], the American Cancer Society (VC 112), and the Leukemia Research Foundation of Chicago.

This content is only available via PDF.